OASIS 133

المعلومات الرئيسية

  • اسم تجاري:
  • OASIS 133
  • يسخدم من اجل:
  • البشر
  • نوع الدواء:
  • الجهاز الطبي

المستندات

  • لعامة الناس:
  • النشرة المعلومات عن هذا المنتج غير متوفر حاليا، يمكنك إرسال طلب لخدمة العملاء لدينا، ونحن سوف يخطر لك في أقرب وقت ونحن قادرون على الحصول عليه.


    طلب نشرة المعلومات لعامة الناس.

الأقلمة

  • متاح في:
  • OASIS 133
    كازاخستان
  • اللغة:
  • العربية

معلومات أخرى

الحالة

  • المصدر:
  • Ecolab
  • تخويل:
  • 985655
  • اخر تحديث:
  • 12-03-2018

ملخص خصائص المنتج

OASIS 133

985655

1 / 8

OASIS 133

0.78 % - 25.0 %

00971 4 8014444

00971 48146800 00971 4 8014000

0020 2 25 37 1195

00212 22 58 25 30 - 35

00971 4 8014444 :

00971 48146800 00971 4 8014000

0020 2 25 37 1195 :

00212 22 58 25 30 - 35 :

10.08.2017

GHS

OASIS 133

985655

2 / 8

:

:

:

:

:

(%)

25155-30-0

5 - 10

Sodium poly(oxyethylene) dodecyl ether sulfate

68585-34-2

1 - 5

Di-propyleneglycol ethers

29911-27-1

1 - 5

(%)

25155-30-0

1 - 5

OASIS 133

985655

3 / 8

-10 °C

50 °C

OASIS 133

985655

4 / 8

7.0 - 9.0

100 %

7.0 - 9.0

OASIS 133

985655

5 / 8

1.01 - 1.03

58.929 mm2/s (40 °C)

OASIS 133

985655

6 / 8

> 5,000 mg/kg :

> 5,000 mg/kg :

OASIS 133

985655

7 / 8

96 h :

LC50

3.2 mg/l :

Sodium poly(oxyethylene) dodecyl ether sulfate

96 h :

LC50

28 mg/l :

Di-propyleneglycol ethers

96 h :

LC50

> 100 mg/l :

OASIS 133

985655

8 / 8

(ADR/ADN/RID)

)

(

)

IMDG/

(

10.08.2017

Regulatory Affairs

  • النشرة المعلومات عن هذا المنتج غير متوفر حاليا، يمكنك إرسال طلب لخدمة العملاء لدينا، ونحن سوف يخطر لك في أقرب وقت ونحن قادرون على الحصول عليه.

    طلب نشرة المعلومات لعامة الناس.



  • وثائق في اللغات الأخرى المتاحة هنا

20-10-2018

Scientific Opinion of Flavouring Group Evaluation 411 (FGE.411): 2‐(4‐methylphenoxy)‐N‐(1H‐pyrazol‐3‐yl)‐N‐(thiophen‐2‐ylmethyl)acetamide from chemical group 30 (miscellaneous substances)

Scientific Opinion of Flavouring Group Evaluation 411 (FGE.411): 2‐(4‐methylphenoxy)‐N‐(1H‐pyrazol‐3‐yl)‐N‐(thiophen‐2‐ylmethyl)acetamide from chemical group 30 (miscellaneous substances)

Published on: Fri, 19 Oct 2018 00:00:00 +0200 EFSA was requested to deliver a scientific opinion on the implications for human health of the flavouring substance 2‐(4‐methylphenoxy)‐N‐(1H‐pyrazol‐3‐yl)‐N‐(thiophen‐2‐ylmethyl)acetamide [FL‐no: 16.133], in the Flavouring Group Evaluation 411 (FGE.411), according to Regulation (EC) No 1331/2008 of the European Parliament and of the Council. The substance has not been reported to occur in natural source materials of botanical or animal origin. It is intende...

Europe - EFSA - European Food Safety Authority Publications

29-8-2018

Grant agreement for piloting the Framework Partnership Agreement between the National data provider organisations in Slovakia and EFSA – Final report

Grant agreement for piloting the Framework Partnership Agreement between the National data provider organisations in Slovakia and EFSA – Final report

Published on: Tue, 07 Aug 2018 00:00:00 +0200 Presented document is the final report of the project GA/EFSA/DATA/2017/01: “Strategic Partnership with Slovakia on Data Quality (Pilot project)”. The report describes national processes and tools in order to implement internal validation and quality control of collected data according to EFSA requirements. A description of the data transmission processes from the National Databases to the EFSA databases, terminology, data mapping and data transformations fo...

Europe - EFSA - European Food Safety Authority Publications

1-10-2018

EU/3/03/133 (Shire Orphan Therapies GmbH)

EU/3/03/133 (Shire Orphan Therapies GmbH)

EU/3/03/133 (Active substance: Icatibant acetate) - Transfer of orphan designation - Commission Decision (2018)6432 of Mon, 01 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/054/02/T/01

Europe -DG Health and Food Safety

2-8-2018

EU/3/14/1351 (Kyowa Kirin Holdings B.V.)

EU/3/14/1351 (Kyowa Kirin Holdings B.V.)

EU/3/14/1351 (Active substance: Recombinant human monoclonal IgG1 antibody for fibroblast growth factor 23) - Transfer of orphan designation - Commission Decision (2018)5289 of Thu, 02 Aug 2018 European Medicines Agency (EMA) procedure number: EMA/OD/133/14/T/02

Europe -DG Health and Food Safety

16-7-2018

Reconcile (Nexcyon Pharmaceuticals Ltd)

Reconcile (Nexcyon Pharmaceuticals Ltd)

Reconcile (Active substance: Fluoxetine) - Centralised - Renewal - Commission Decision (2018)4770 of Mon, 16 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/133/R-18

Europe -DG Health and Food Safety

18-5-2018

EU/3/14/1252 (Chiesi Farmaceutici S.p.A.)

EU/3/14/1252 (Chiesi Farmaceutici S.p.A.)

EU/3/14/1252 (Active substance: Cysteamine bitartrate) - Transfer of orphan designation - Commission Decision (2018)3133 of Fri, 18 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/164/13/T/01

Europe -DG Health and Food Safety

18-5-2018

EU/3/17/1936 (Pharma Gateway AB)

EU/3/17/1936 (Pharma Gateway AB)

EU/3/17/1936 (Active substance: 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea) - Transfer of orphan designation - Commission Decision (2018)3133 of Fri, 18 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/119/17/T/01

Europe -DG Health and Food Safety